TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07193810: Exploratory Clinical Study on the Safety and Preliminary Efficacy of CC312 in the Treatment of Relapsed/Refractory Autoimmune Diseases

Sponsor: CytoCares Inc · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,090,820

Rescue Site Savings

+$3,354,780

Unlock Full NCT07193810 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07193810 Rescue Dossier →